On July 13, 2022, the Brazilian federal health regulatory agency (Anvisa) granted emergency use of CoronaVac (Sinovac Biotech) to protect children between the ages 3 and 5 from SARS-CoV-2 based on a re-evaluation of clinical trial research from China,1 Chile2,3 and Brazil.4 This is a promising development as 41,395 children in this age group have been hospitalized for Severe Acute Respiratory Infection, SARI, (4470 COVID-confirmed), and 450 have died (144 COVID-confirmed) since the onset of the uncontrolled and preventable pandemic until the 22nd epidemiological week (epi week) of 2022 (see Appendix 1). Relative to 2019, the risk of SARI hospitalization in 2021 was 4.7 higher, and deaths have increased by 2 in this age group.
The Solidary Research Network was formed to help improve the standard, calibrate the focus and improve the quality of federal, state and municipal government policies that seek to respond the COVID-19 crisis with the aim of helping to save lives.
